Instituto Rosenbusch

Instituto Rosenbusch SGA/Revenue

The SGA to Revenue Ratio of Instituto Rosenbusch (ROSE2.BA) as of Nov 5, 2026 is 23.03 %. In the previous year, SGA to Revenue Ratio was 26.72 % — a change of -13.81% (lower).

SGA/Revenue

23.03 %

YoY

-13.81%

Last updated:

SGA to Revenue Ratio of Instituto Rosenbusch is 2024 23.03 % . SGA to Revenue Ratio of Instituto Rosenbusch was 2023 26.72 % . It decreases by -13.81% lower compared to the previous year.

The Instituto Rosenbusch SGA/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

SGA/Revenue
Date
SGA/Revenue
Jan 1, 2017
34.38 ARS
Jan 1, 2018
27.18 ARS
Jan 1, 2019
37.92 ARS
Jan 1, 2020
24.28 ARS
Jan 1, 2021
26.82 ARS
Jan 1, 2022
25.28 ARS
Jan 1, 2023
26.72 ARS
Jan 1, 2024
23.03 ARS
The Instituto Rosenbusch SGA/Revenue history
YEARSGA/RevenueYoY
23.03 %-13.81%
26.72 %+5.69%
25.28 %-5.75%
26.82 %+10.45%
24.28 %-35.96%
37.92 %+39.49%
27.18 %-20.94%
34.38 %+20.07%
28.64 %-0.27%
28.71 %+8.73%
26.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Instituto Rosenbusch Stock analysis

What does Instituto Rosenbusch do? Instituto Rosenbusch SA generates revenue through the manufacture and marketing of veterinary pharmaceuticals and biological products. The company's Pharmaceutical line includes antibiotics, antimastitics, antimycotics, antiparasites, vitamins, minerals, and other chemotherapies, while its Biological line comprises vaccines for cattle, equines, porks, sheeps, and dogs. The firm also earns income from slaughtering and providing meat products. Subsidiaries such as Laboratorios Rosenbusch SA, Laboratorios Bolivar SA, and Rosenbusch Paraguay SA contribute to the company's operations and revenue streams. The primary customers for veterinary pharmaceuticals are livestock farmers and veterinarians, while meat products are sold to consumers and food retailers. The company's product segments are clearly defined by their categories: Pharmaceutical for animal health treatments and Biological for disease prevention through vaccines. Meat provision targets the broader food market, extending the company's reach beyond veterinary services. Institutional buyers of veterinary products include farms and veterinary clinics, which purchase antibiotics, vaccines, and other treatments. The meat segment serves retail and wholesale food markets, with subsidiaries supporting production and distribution. The company's focus on both animal health and meat provision creates a diversified revenue model, leveraging its subsidiaries for expanded market coverage. Instituto Rosenbusch is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Instituto Rosenbusch stock

SGA to Revenue Ratio of Instituto Rosenbusch is 23.03 % in 2024.

SGA to Revenue Ratio of Instituto Rosenbusch changed from 26.72 % to 23.03 %, representing a -13.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of SGA to Revenue Ratio Instituto Rosenbusch since 2006 – with annual values, charts, and detailed analysis.

The SGA/Revenue ratio shows what percentage of revenue is consumed by selling, general, and administrative costs. Lower ratios indicate greater operating efficiency.

A 'good' varies by industry and company stage. On Eulerpool, you can compare SGA to Revenue Ratio's Instituto Rosenbusch with sector peers and the industry average to assess whether it is attractive.

To evaluate SGA to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for SGA to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Instituto Rosenbusch

All Key Metrics — Instituto Rosenbusch